COMMUNIQUÉS West-GlobeNewswire

DLH Awarded New NIH Cybersecurity Operations Task Order Valued at Up to $19.1 Million
28/09/2026
ATLANTA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
28/09/2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
28/09/2026
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown Findings validate that physiological lipoprotein levels are sufficient [...]
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
28/09/2026
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected [...]
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
28/09/2026
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships [...]
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
28/09/2026
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient Burden
28/09/2026
POMPANO BEACH, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the publication of a milestone study, Peripheral Nerve [...]
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28/09/2026
Initial data expected in the first half of 2027 LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing [...]
Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
28/09/2026
Expands Company’s Portfolio of Advanced Neurovascular Catheters to Support Treatment in Smaller and More Distal Anatomies WEST JORDAN, Utah, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
28/09/2026
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating [...]
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
28/09/2026
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2- [...]
GuideAI Health Corp. and vRad Renew Data Exclusivity Agreement to Develop AI Models for the Detection and Characterization of Multiple Vascular Diseases
28/09/2026
Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
28/09/2026
Following successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101 ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company developing stem- [...]
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
28/09/2026
Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline SAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio [...]
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
28/09/2026
PMS is a severely disabling genetic disorder related to autism U.S. prevalence is estimated at approximately 1 in 7,300 people HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an Important [...]
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
28/09/2026
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future [...]
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
28/09/2026
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and [...]
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
28/09/2026
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need Non-dilutive funding for SCY- [...]
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09/2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 ( [...]

Pages